Back to Search Start Over

Impact of time to start of tranexamic acid treatment on rebleed risk and outcome in aneurysmal subarachnoid hemorrhage

Authors :
Germans, Menno R; https://orcid.org/0000-0003-2185-4526
Tjerkstra, Maud A; https://orcid.org/0000-0001-9060-3435
Post, René; https://orcid.org/0000-0001-7844-6262
Brenner, Amy
Vergouwen, Mervyn DI; https://orcid.org/0000-0002-6823-1628
Rinkel, Gabriël Je
Roos, Yvo Bwem; https://orcid.org/0000-0001-9205-5882
van den Berg, René
Coert, Bert A
Vandertop, W Peter; https://orcid.org/0000-0001-5417-0265
Verbaan, Dagmar; https://orcid.org/0000-0002-9212-5470
Germans, Menno R; https://orcid.org/0000-0003-2185-4526
Tjerkstra, Maud A; https://orcid.org/0000-0001-9060-3435
Post, René; https://orcid.org/0000-0001-7844-6262
Brenner, Amy
Vergouwen, Mervyn DI; https://orcid.org/0000-0002-6823-1628
Rinkel, Gabriël Je
Roos, Yvo Bwem; https://orcid.org/0000-0001-9205-5882
van den Berg, René
Coert, Bert A
Vandertop, W Peter; https://orcid.org/0000-0001-5417-0265
Verbaan, Dagmar; https://orcid.org/0000-0002-9212-5470
Source :
Germans, Menno R; Tjerkstra, Maud A; Post, René; Brenner, Amy; Vergouwen, Mervyn DI; Rinkel, Gabriël Je; Roos, Yvo Bwem; van den Berg, René; Coert, Bert A; Vandertop, W Peter; Verbaan, Dagmar (2024). Impact of time to start of tranexamic acid treatment on rebleed risk and outcome in aneurysmal subarachnoid hemorrhage. European Stroke Journal:Epub ahead of print.
Publication Year :
2024

Abstract

INTRODUCTION: The ULTRA-trial investigated effectiveness of ultra-early administration of tranexamic acid (TXA) in subarachnoid hemorrhage (SAH) and showed that TXA reduces the risk of rebleeding without concurrent improvement in clinical outcome. Previous trials in bleeding conditions, distinct from SAH, have shown that time to start of antifibrinolytic treatment influences outcome. This post-hoc analysis of the ULTRA-trial investigates whether the interval between hemorrhage and start of TXA impacts the effect of TXA on rebleeding and functional outcome following aneurysmal SAH. PATIENTS AND METHODS: A post-hoc comparative analysis was conducted between aneurysmal SAH patients of the ULTRA-trial, receiving TXA and usual care to those receiving usual care only. We assessed confounders, hazard ratio (HR) of rebleeding and odds ratio (OR) of good outcome (modified Rankin Scale 0-3) at 6 months, and investigated the impact of time between hemorrhage and start of TXA on the treatment effect, stratified into time categories (0-3, 3-6 and >6 h). RESULTS: Sixty-four of 394 patients (16.2%) in the TXA group experienced a rebleeding, compared to 83 of 413 patients (19.9%) with usual care only (HR 0.86, 95% confidence interval (CI): 0.62-1.19). Time to start of TXA modifies the effect of TXA on rebleeding rate (p < 0.001), with a clinically non-relevant reduction observed only when TXA was initiated after 6 h (absolute rate reduction 1.4%). Tranexamic acid treatment showed no effect on good outcome (OR 0.96, 95% CI: 0.72-1.27) with no evidence of effect modification on the time to start of TXA (p = 0.53). DISCUSSION AND CONCLUSIONS: This study suggests that the effect of TXA on rebleeding is modified by time to treatment, providing a protective, albeit clinically non-relevant, effect only when started after 6 h. No difference in functional outcome was seen. Routine TXA treatment in the aneurysmal SAH population, even within a specified time frame, is not recommended to impro

Details

Database :
OAIster
Journal :
Germans, Menno R; Tjerkstra, Maud A; Post, René; Brenner, Amy; Vergouwen, Mervyn DI; Rinkel, Gabriël Je; Roos, Yvo Bwem; van den Berg, René; Coert, Bert A; Vandertop, W Peter; Verbaan, Dagmar (2024). Impact of time to start of tranexamic acid treatment on rebleed risk and outcome in aneurysmal subarachnoid hemorrhage. European Stroke Journal:Epub ahead of print.
Notes :
application/pdf, info:doi/10.5167/uzh-259400, English, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1443059285
Document Type :
Electronic Resource